Arkolith/Insider Trading/THRX/Form 4

Hayden Donald J JR

DirectorTheseus Pharmaceuticals, Inc. (THRX) · full profile →Form 4 · filed Jan 3, 2023
Net Buying
Open-Market Buys
$50K
Open-Market Sells
$0
Net Open-Market Flow
$50K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 30, 2022Buy(P)10K$5.00$50K10K
Dec 29, 2022Buy(P)100$5.00$500100

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-000080) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML